Shots: Linnaeus will conduct 6 additional P-II cohorts evaluating LNS8801 + Keytruda in several cancer indications while the companies are currently evaluating the combination in patients who had previously responded […]readmore
Tags : Advanced Cancer
Shots: The first patient has been dosed in P-l/ll adaptive-design study assessing the safety, tolerability, pharmacokinetics, and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit […]readmore
Shots: The companies enter into an agreement to evaluate the combination of Innovent’s Tyvyt with Shenogen’s SNG1005 for the patients with advanced cancer Shenogen has in-licensed SNG1005 and has exclusive […]readmore